^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Proleukin (aldesleukin)

    i
    Other names: rIL-2, recombinant human interleukin-2, 125-L-Serine-2-133-interleukin 2, r-serHuIL-2
    Company:
    Clinigen, Iovance Biotherap, Novartis
    Drug class:
    IL-2 stimulant, CD122 agonist
    Related drugs:
    2d
    Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R (clinicaltrials.gov)
    P2, N=60, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    cytarabine • etoposide IV • idarubicin hydrochloride • Proleukin (aldesleukin) • busulfan • Neupogen (filgrastim)
    2d
    T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (clinicaltrials.gov)
    P1, N=36, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Site plans to become a site for a multicenter study of this therapy
    Trial termination • IO biomarker
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Zuplenz (ondansetron oral dispersible film)
    10d
    Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    14d
    Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=27, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    24d
    Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (clinicaltrials.gov)
    P1/2, N=8, Terminated, Alaunos Therapeutics | N=180 --> 8 | Active, not recruiting --> Terminated; Funding
    Enrollment change • Trial termination • IO biomarker
    |
    Proleukin (aldesleukin)
    1m
    Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma (clinicaltrials.gov)
    P2, N=17, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    2ms
    Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD) (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, University of Oxford | Trial completion date: Sep 2022 --> Sep 2026
    Trial completion date
    |
    Proleukin (aldesleukin)
    2ms
    IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients (clinicaltrials.gov)
    P2, N=29, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Aug 2025 --> Mar 2026
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Proleukin (aldesleukin)
    2ms
    Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma (clinicaltrials.gov)
    P=N/A, N=19, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2025
    Trial completion • Trial completion date
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    2ms
    Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (clinicaltrials.gov)
    P=N/A, N=13, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600 • BRAF wild-type
    |
    Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    2ms
    Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=15, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Proleukin (aldesleukin) • CIML NK
    3ms
    Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=159, Recruiting, Aulos Bioscience, Inc. | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • Bavencio (avelumab) • Proleukin (aldesleukin) • imneskibart (AU-007)